Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nifedipine
Drug ID BADD_D01566
Description Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]
Indications and Usage For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
Marketing Status Prescription; Discontinued
ATC Code C08CA05
DrugBank ID DB01115
KEGG ID D00437
MeSH ID D009543
PubChem ID 4485
TTD Drug ID D04OSE
NDC Product Code 50090-5284; 61919-319; 55289-798; 11014-0036; 70771-1367; 67877-756; 70771-1192; 53808-1118; 50742-261; 24979-010; 52932-0711; 50090-0695; 50742-260; 55289-907; 71335-0497; 68071-3347; 68382-685; 50090-3034; 71610-290; 68682-105; 68071-4411; 71205-965; 62175-261; 61919-192; 0395-8095; 24979-011; 48292-0034; 51927-0233; 63759-7009; 63187-875; 49452-4847; 71205-412; 23155-195; 71335-0744; 59651-296; 62175-262; 72214-503; 12527-8861; 70896-2026; 0228-2497; 68382-688; 71335-1721; 38779-0280; 69315-211; 55154-4690; 46438-0052; 50090-4158; 51927-2311; 0228-2530; 67877-758; 60524-002; 68682-107; 55154-8177; 52133-0028; 50268-598; 59651-297; 0069-2670; 24979-009; 0069-2650; 68084-598; 51407-622; 50090-0697; 51552-0720; 70518-2679; 71610-055; 0904-7082; 68071-4097; 51407-623; 11014-0038; 71052-650; 70771-1190; 60429-047; 68382-687; 72789-219; 49452-4852; 50090-1843; 11014-0341; 70771-1365; 23155-194; 71610-144; 63629-7215; 0904-7080; 68682-109; 71205-964; 60429-163; 68071-2619; 50742-621; 60429-048; 70807-503; 60592-507; 51407-624; 62175-260; 48589-0006; 12527-8841; 68382-690; 68382-686; 12527-0787; 52133-0009; 11014-0342; 79572-025; 50742-262; 62991-1106; 0069-2660; 67877-757; 50090-5328; 68084-603; 50090-4442; 50742-620; 50268-601; 0904-7081; 60429-049; 59762-1004; 68645-513; 12527-8851; 68084-597; 50090-4234; 71335-1550; 69315-212; 68071-4558; 50268-599; 71610-012; 68645-512; 68682-108; 68682-106; 70771-1191; 66267-831; 68981-039; 50742-622; 50090-4249; 46438-0635; 68071-4334; 50268-597; 11014-0035; 71205-963; 60687-425; 59651-295; 68071-4281; 68071-3281; 65427-250; 71335-0489; 68382-689; 70771-1366; 68788-7642; 68788-8164
Synonyms Nifedipine | Bay-1040 | Bay 1040 | Bay1040 | BAY-a-1040 | BAY a 1040 | BAYa1040 | Cordipin | Cordipine | Corinfar | Korinfar | Nifangin | Nifedipine Monohydrochloride | Monohydrochloride, Nifedipine | Procardia | Procardia XL | Nifedipine-GTIS | Nifedipine GTIS | Vascard | Adalat | Fenigidin
Chemical Information
Molecular Formula C17H18N2O6
CAS Registry Number 21829-25-4
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionS-adenosylhomocysteine hydrolase-like protein 1O43865Not Available7054240; 6330251; 7059972
Gingival hyperplasiaAndrogen receptorP10275T1121126152187
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrial fibrillation02.03.03.002--
Atrial septal defect03.07.02.002; 02.04.02.0090.000336%Not Available
Atrioventricular block02.03.01.0020.000263%Not Available
Atrioventricular block complete02.03.01.0030.000336%
Back pain15.03.04.005--
Basal cell carcinoma23.08.02.001; 16.03.02.0010.000336%Not Available
Bezoar07.11.01.0080.000336%Not Available
Blindness06.02.02.001; 17.17.01.0030.001009%Not Available
Blindness transient17.17.01.004; 06.02.02.002--Not Available
Blindness unilateral17.17.01.016; 06.02.02.009--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood creatine phosphokinase increased13.04.01.0010.000673%
Blood creatinine increased13.13.01.0040.000504%
Blood glucose increased13.02.02.0020.000504%Not Available
Blood magnesium decreased13.11.01.0080.000336%Not Available
Blood pressure decreased13.14.03.0020.001345%Not Available
Blood pressure increased13.14.03.0050.002186%Not Available
Blood pressure systolic decreased13.14.03.0070.000336%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.003027%Not Available
Bradycardia foetal18.03.02.006; 02.03.02.0180.000132%Not Available
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Breast pain21.05.05.003--
Bronchiectasis22.03.02.0050.000336%Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Bundle branch block left02.03.01.0070.000504%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000504%Not Available
Cardiac arrest02.03.04.0010.001141%
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 14 Pages